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Abstract
Background: The PAPHIO study; a randomized controlled trial with 2X2 crossover design will implement a self-
directed physical activity program in which participants will engage in self-monitoring and receive motivational
interviewing to enhance physical activity adherence. The study aims to determine the effects of 24 weeks self-
directed activity combined with motivational interviewing (MI) on (i) psychological health, (ii) quality of life (QoL)
and (iii) immune function in female breast cancer survivors.
Methods: The study will recruit 64 female breast cancer survivors within 3 years of diagnosis and at least 6 months
post primary treatments at Western Health Sunshine Hospital, Melbourne, Australia. They will be randomly allocated
to immediate intervention (IIG group) or delayed intervention groups (DIG group) in a 1:1 ratio. All participants will
be given a wearable device (Fitbit Alta HR) and undertake self-directed physical activity for 24 weeks and will
receive MI for 12 weeks (IIG; during week 0 to week 12 and DIG; during week 13 to week 24). Participants’ daily step
count and the changes of immune cell functionality will be assessed at the beginning (week 1: T1), week 12 (T2)
and week 24 (T3) of the program. Physical activity adherence will be assessed at T2 and T3. Participants will also
complete four questionnaires assessing exercise self-regulation (BREQ2), exercise barrier and task self-efficacy,
mental health (DASS-21) and QoL (FACT-B) at three time points (T1 to T3). Linear-mixed models will be used to
assess the relationship between physical activity volume by step counting and mental health (DASS-21), QoL (FACT-
B), immune biomarkers, self-regulation (BREQ2) and self-efficacy at T1, T2 and T3;between 2 groups.
Discussion: We expect this physical activity intervention to be acceptable and beneficial to the participants in
terms of psychological and immunological well-being with the potential outcomes to be implemented more
widely at relatively low cost to these or other patient populations.
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Background
Breast cancer is a common malignant disease leading to
physical and psychological distress in females worldwide
[1, 2]. Approximately 2.1 million women suffered from
this disease and 626,000 deceased across the world in
2018 [3]. . The occurrence rate of breast cancer has dra-
matically increased in 22 out of 39 countries from 2008
to 2012, whereas the global death rate has gradually
dropped [4]. The global trend of breast cancer increases
awareness in the availability of breast cancer care pro-
gram [4].
Breast cancer survivors may have mental distress
mainly due to long-term treatments [5].Currently, sur-
vivorship programs, especially physical activity programs
have emphasised strategies to enhance psychosocial
well-being [6, 7]. Psychological interventions including
emotional ventilation, adjustment skill training and self-
efficacy promotion techniques have been applied in im-
proving their mental wellness over the decades [6, 8].
Physical activity, especially moderate intensity aerobic
exercise for female breast cancer survivors, have been
noted in a number of studies to be beneficial to breast
cancer outcomes, decreasing the mortality rate by > 30%
and reducing the recurrence rate [9]. As a result of phys-
ical activity, there is a reduction in the total body fat as
well as a number of inflammatory and immunological
biomarkers which could contribute to better outcomes
in breast cancer survivors [10, 11]. Moderate aerobic ex-
ercise and combination of aerobic and resistant training
in breast cancer women ranging between 15 and 24
weeks could possibly activate immune cells such as NK
cell cytotoxic activity and lymphocytes [12, 13]. Further-
more, a 12-weeks aerobic exercise training at home in
breast cancer survivors reduces the level of epithelial
neutrophil activating protein and pro-inflammatory cy-
tokines [14].
Approximately one third of patients with cancer re-
duce their physical activity after diagnosis and almost
70% of them will not reach the exercise recommendation
for cancer patients [15].. 30% Of breast cancer survivors
with early phase (stage 0 to 3) breast cancer have re-
ported physical activity cessation during 12 months
follow-up after participation in a 6 months RCT [16].
The cessation may be associated with the resumption of
their previous domestic tasks and work [16]. Physical ac-
tivity barriers in older breast cancer survivors are related
to physical tiredness and lack of time management skills
[17]. In addition, some breast cancer survivors have low
confidence in the benefits of physical activity in minim-
izing adverse effects of breast cancer and treatment [18].
The challenge of recruiting patients with advanced stage
of cancer is to deal with their cancer-related fatigue in
particular the side effect of treatments [15].
Physical activity and motivation for activity adherence in
breast cancer survivors
Adoption and adherence to physical activity programs
amongst cancer survivors are challenging due to their
physical and mental vulnerability [19]. As such, in this
study we developed an intervention which maximizes
feasibility, sustainability and generalisability. This study
will prescribe self-directed physical activity to breast
cancer survivors. Many of self-directed techniques for
physical activity adherence in participants with advanced
stage of heterogeneous cancers have been used in re-
search studies, such as partially advised and home-based
program, exercise class teaching and peer support walk-
ing group programs [20]. Many of the programs have
achieved high percentages of exercise adherence, redu-
cing fatigue and improving QoL [20].
An important factor to adopt and adhere to a physical ac-
tivity program is an individual’s motivation. To this end, a
number of behavioural change strategies have been re-
ported which enhance motivation and adherence [21]. Two
of these strategies are Motivational Interviewing (MI) and
self-monitoring. MI is a conversation technique used by a
professional during consultation when making health be-
haviour changes [22], and has been effectively used to bring
about behavioural change in health promotion programs
for the general population. This includes changes in eating
behaviour, alcohol cessation and adoption of an active life
style [23]. More specifically, face-to-face and phone based
MI has been implemented successfully to enhance self-
efficacy and reduce resistance against physical activity in
breast cancer survivors [24, 25].. On the other hand, self-
monitoring,one of the important concepts in self-regulation
theory, is an auditing mechanism of individual performance
in relation to an individual’s cognitions, beliefs and emo-
tions [26]. Some digital devices have the ability to promote
physical activity through self-monitoring concept [27]. For
example, step counting gadgets including pedometers, can
effectively monitor physical activity in terms of daily steps.
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Such devices have been utilised for promotion of physical
activity in clinical trials [28] especially in breast cancer
patients and survivors [29, 30]. Step counters help in moni-
toring individual’s physical activity behaviour and can result
in increased motivation and ultimately adherence to long-
term physical activity behaviour [31].
To understand participants’ motivation to self-directed
physical activity, self-determination theory (SDT) has been
effectively used to enhance insight in physical activity be-
haviour and motivation in breast cancer survivors [32].
According to SDT motivation to engage in behaviour lies
on a continuum ranging from extrinsic (controlled by
external factors) to intrinsic (individual interest and pref-
erence). The theory predicts that intrinsic-motivation
might enhance confidence in task accomplishment (com-
petence), independent action (autonomy) and the feeling
of connection to others (relatedness) [32]. Our study will
assess how self-regulation and motivational interviewing
might change participants motivational orientation over
the intervention period using the behavioural regulations
in exercise questionnaire (BREQ2 [33];).
Self-efficacy, an important concept in social cognitive the-
ory, has been shown to be a predictor for physical activity
behaviour and adherence in breast cancer patient [34]. In
this project two types of efficacy beliefs will be examined.
First, we will explore exercise barriers self-efficacy, which
will examine the participants’ confidence to overcome or
deal with barriers to their exercise participation. Secondly,
this project will examine task self-efficacy beliefs In particu-
lar, it will examine the self-efficacy beliefs of the partici-
pants to engage in exercise behavior [34]. To measure this,
the project will use the nine-item barriers self-efficacy [34]
and four-item task self-efficacy questionnaire [34].
Study goals and objectives
The study has an overall aim to determine the effects of
24 weeks self-directed activity combined with motiv-
ational interviewing on (i) psychological health (depres-
sion, anxiety, stress), (ii) quality of life (QoL; physical,
social/family, emotional and functional) and (iii) im-
mune function in female breast cancer survivors. In
addition, we will explore the dose-response relationship
between exercise volume (step count) and the outcome
measures.
Study design
This study is a randomised crossover trial; a single site
research project conducted at Brest Cancer Service
Clinic, Western Health (Sunshine Hospital) Australia.
Potential participants will be prescribed with a Fitbit
Alta HR tracker for a 24-week-self-directed activity and
will receive motivational interviewing for 12 weeks (Im-
mediate intervention group; during week 0 to week 12
and Delayed intervention group; during week 13 to week
24). The study protocol through 24 weeks is illustrated
in Fig. 1.
Inclusion criteria
Female breast cancer survivors 18 years and older who
are within 3 years of diagnosis and at least 6 months
post active treatment; operation, chemotherapy and/or
radiotherapy [stages 0 to 3 including those with ductal
carcinoma in situ (DCIS)], will be recruited. Survivors
on hormonal therapy such as, tamoxifen and aromatase
inhibitors as well as immune targeted therapy (Hercep-
tin) will be eligible to participate because these hormo-
nal and cell surface blockages do not have direct effects
on immune cells and adiposity-related biomarkers in
breast cancer. The study will also include participants
who are unable to read/ write English but are literate and
English speaking. For participants with non-English liter-
acy, translators will be used to obtain informed consent
and the study will apply the questionnaires that have been
validated in other languages such as Vietnamese, Greek,
Chinese and Macedonian. This study plans to recruit par-
ticipants from Breast cancer care service of Sunshine Hos-
pital, Western Health, Melbourne, Australia.
Exclusion criteria
Participants who are undergoing active treatments (sur-
gery, chemotherapy and radiation) as well as those less
than 6 months post active treatment. Likewise, those indi-
viduals with cognitive impairment and unable complete
the questionnaires will be excluded. Participants with
known metastatic disease will also be excluded from the
study. The participant will be withdrawn from the study if
they develop cancer recurrence or metastases during the
study period.
Recruitment
The study will recruit participants who are breast cancer
survivors within 3 years of diagnosis and at least
6 months post primary treatments. Eligible participants
will be randomly allocated to immediate intervention or
delayed intervention groups in a 1:1 ratio after comple-
tion of informed consent. The participants will be re-
cruited from Breast cancer care service, Western Health
Sunshine campus in Melbourne. Recruitment strategies
will include public media (poster advertising or flyer)
and individual contact introduced by their physician
[35]. All participants have to be approved by their phys-
ician for engagement in the physical activity program of
this research and the screening process will be con-
ducted before obtaining consent.
The study will commence at Western Health Sunshine
campus following ethical approval from Melbourne
Health Human Research Ethics Committee (MH HREC)
and Western Health research governance authorization
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[36]. Based on our power calculation we aim to recruit
64 participants.
Randomisation
The study design is a two-armed RCT with a crossover
design. Sequence generation will be conducted by simple
randomisation following patient informed consent. The
participants will be randomly allocated to either IIG or
DIG in 1:1 ratio by computerised number generator. Al-
location concealment by enclosing the allocation in
sealed envelopes will be used to prevent selection bias
[37]. The allocation concealment will be conducted by a
Fig. 1 Study protocol through 24 weeks trial
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third party to prevent researchers from affecting group
assignment. The participants in both groups will be pre-
scribed a self-directed physical activity for 24 weeks. The
IIG will receive MI from week 1 to week 12, whereas
DIG will receive the same MI intervention from weeks
13 to 24.Allocation concealment technique will be
applied in process of randomisation. During weeks 1 to
week 12, theIIG will perform self-directed physical activ-
ity and receive MI. On the other hand, the DIG will per-
form self-directed physical activity without MI. During
week 13 to week 24, DIG will continue self-directed
physical activity with MI. Whereas IIG will perform
physical activity but will no longer be given MI.
Methods of intervention
Self-directed physical activity
Participants will perform a 24-week period of self-
directed, pedometer controlled physical activity [38, 39].
All participants will be given a step-count tracker devise
(Fitbit Alta HR) and investigators will explain the pre-
scribed pedometer-based activity to participants. Fitbit
Alta HR is a wearable gadget and can be used to monitor
step count. The participants’ activity engagement will be
accompanied by individual face-to-face and phone call MI
[22]. Participants will be taught how to operate the Fitbit
and will be taken on a 10min walk to experience a moder-
ate level of exertion.. At week 1 (baseline or T1), all partic-
ipants will be prescribed to assess and record their activity
using the Fitbit monitoring device through its application
via computer or smartphone to establish their baseline
physical activity volume by step count. Following this, they
will be advised to perform their activity on their own pace
as tolerated and will wear the Fitbit during the daytime or
when they are available for physical activity throughout
the 24 weeks. Individual participants will be advised and
motivated to gradually increase their daily steps on phys-
ical activity at moderate intensity exertion or at their per-
ception of taking some efforts but can talk during physical
activity (the recommendation by the department of health,
Australian government) [40] during face-to-face and over
the phone MI. The participants will be advised for safety
during physical activity. They will be suggested to stop
physical activity if adverse symptoms occur such as chest
pain or pain down to arms, dizziness, difficulty breathing,
unusual rapid heart rate, and sever fatigue. The researcher
will suggest to the participant to inform their family mem-
bers and take a mobile phone with them before they go
out to exercise. They will be also advised to take record of
their daily steps in their notebook. All participants will be
informed that the researcher will track the participants’
step count and tracker usage time via Fitbit connect appli-
cation. Individual average daily step count, and activity
level will be assessed at baseline (T1), week 12 (T2), and
week 24 (T3).
Motivational interviewing
MI will be used in encouraging participants through
open-end questions, friendly and supportive communi-
cation and induction of behavioral changes [22, 24].
Each MI will be conducted through four phases of con-
versation comprising: 1) Engage, 2) Focus, 3) Evoke, and
4) Plan [22]. The study will use the dialog of MI guided
by Mentha Counselling and will be conducted by a
counsellor who experienced MI There will be a 20 min
face-to-face in week 1 and three phone MI sessions (15
min) at weeks 2, 4 and 9 for IIG. For DIG this will take
place at weeks 12, 13, 15 and 20.
Blood collection and storage
Approximately 20 ml of blood will be collected via a
venipuncture at T1, T2 and T3 for both groups. Whole
blood will be collected into a tube containing anticoagu-
lant and centrifuged immediately after collection or on
the same day approximately 7 h later.
Isolation of peripheral blood mononuclear cells
(PBMCs) by density gradient configuration using Ficoll-
Paque will be used for immune cell functions. PBMCs
will be stored in refrigerator not longer than 1 day and
then use flow cytometry to assess the composition of the
isolated PBMC populations.
Method of data collection and outcome measurements
Primary outcomes
Psychological health and QoL Levels of stress, depres-
sion and anxiety will be assessed using the DASS 21
[41]. The DASS21 has been validated for breast cancer
survivors and has good reliability [42]. In addition, the
FACT-B version 4 [43] will be used to measure QoL.
This cancer specific questionnaire is well validated and
has good reliability and measures physical, social/family,
emotional and functional well-being aspects and breast
cancer specific conditions [43, 44]. Participant will
complete these instruments at baseline; week 1 (T1),
week 12 (T2), and week 24 (T3).
Immune function PBMC cells (white blood cells) will
be isolated from blood and PBMC assessed for changes
at the cellular level by flow cytometric analysis [45] at
baseline; weeks 1 (T1), 12 (T2), and 24 (T3). Cell surface
markers, CD40, CD80, CD83, CD86, MHC-I, MHC-II,
CD14, CD16, CD206, CD209 will be assessed by flow cy-
tometry technique [45] to determine the changes after
the program. In addition, the ratio of type 1 and type 2
T helper (Th1/Th2) cytokines secreted by monocytes
and T cells will be determined to understand any cellu-
lar changes following exercise activity.
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Secondary outcomes
Average daily step count Participants will record their
own daily steps through the Fitbit Alta HRapplication,
upload their step count on their computer or smart-
phone and send the data to the researcher by email or
phone call weekly. They can also record their steps from
the tracker in a provided notebook. Researchers can
track an individual’s daily step count via Fitbit Alta HR
application on a computer or smartphone. The average
daily step count will be calculated at baseline at each of
the 12 weeks of the intervention program.
Adherence in step tracker usage The participants’
adherence to self-directed physical activity will be evalu-
ated by their compliance by wearing the Fitbit Alta HR.
The adherence rate of fitness tracker usage can be an
indicator for exercise program feasibility in breast cancer
patients [46]. The adherence will be defined as step
count tracker wearing time with data capture (daily
hours and the number of wearing days) [46]. The mean
of daily hours and number of wearing days per week will
be calculated at the end of week 12 and week 24 of self-
directed physical activity period [31].
Exercise self-regulation The participant’s self-regulation
for exercise will be assessed using the behavioral regulations
in exercise questionnaire version 2 (BREQ2) [33] on three
occasions. This five level-Likert scale-questionnaire has 19
items assessing exercise self-regulation which consists of
five categories: external, introjected, identified, intrinsic and
un-motivated [33]. The psychometric properties of the
BREQ2 is adequate to assess self-regulation for exercise in
breast cancer survivors [47].
Exercise barrier and task self-efficacy The nine item
rating barrier self-efficacy scale will be used to assess the
confidence of participants performing exercise when
experienced some difficulties. Task self-efficacy will be
assessed with a four items scale. This questionnaire was
validated and tested for internal consistency in women
with breast cancer during treatment period [34]. Efficacy
beliefs will be assessed at the start and end of the trial
(see study outcomes measurement in Table 1).
Statistical methods
Sample size estimation and justification
Based on a power of .8, alpha of .05 and large effect size
in change in FACT-B (Cohen’s d = 2.23) from previous
studies [48] we calculated that a minimum of 53 partici-
pants are required. Considering a 10–20% drop-out rate
in exercise studies we decided to recruit a minimum of
64 participants (n = 32 in each of the two conditions).
Analysis of data
Baseline descriptive statistics (mean, standard deviation
for continuous data and percentage for categorical data)
will be used to describe the distribution of personal data
and variables between two groups of participant (e.g.,
age, breast cancer health history, body compositions,
and blood pressure). Independent T-test will be used to
compare means for continuous data and the Pearson
Chi square will be used for testing the difference in dis-
tribution of a categorical variable at baseline [49].
Linear-mixed models will be used to identify the relation-
ship between physical activity volume by step counting and
mental health (DASS-21), QoL (FACT-B), self-regulation
(BREQ2) and self-efficacy at T1, T2 and T3; the relation-
ship between activity volume by step counting and immune
biomarker changes at T1,T2, and T3. The models will also
be used to control for the effect of covariates or confound-
ing factors and to manage for missing data.
Data security and confidentiality
The patient’s personal information and health history
which are necessary for this research study will be
Table 1 Study outcomes measurement for both groups of participant
Outcome measurement Method Week 1
Baseline (T1)
Week 12
(T2)
Week 24
(T3)
Primary outcomes
Psychology health DASS-21 x x x
QoL FACT-B version 4 questionnaire x x x
Immune cell functions Isolation of peripheral blood mononuclear cells x x x
Secondary outcomes
Daily step count/Average
activity volume assessment
Step count tracker x x x
Adherence in pedometer usage Step count tracker wearing time with data capture
(daily hours and the number of wearing days)
x x
Exercise self-regulation; BREQ2 x x x
Exercise barrier and task self-efficacy Exercise barrier and task self-efficacy rating scale x x x
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protected for their privacy and confidentiality [50]. All
data of participants will be recorded adequately and
stored in a secure, password protected databank Agree-
ments involving data ownership and storage will be done
between Western health and Victoria University. This
study has planned to hold clinical trials research data for
15 years or more based on circumstances [36]. It is pos-
sible to keep files of hard copy and electronic files in a
research office at Sunshine Hospital. A locked filing cab-
inet and a computer for research data can only be
accessed by agreed members of the research team. More
specifically, the researchers will have a backup or re-
served storage [36]. For destruction of the data, hard
copy will be shredded by hospital and university office’s
shredder. Digital information will be destroyed by delet-
ing or overwriting the files. According to the protection
of participants’ privacy, personal, health related data and
clinical outcomes will be kept and reported in coded or
reversibly anonymised technique. Re-identifiable infor-
mation will be used for data management (name will be
removed and replaced by a code which can be re-
identified for relating the different data sets and data
verification) [36].
Discussion
Self-directed physical activity in this clinical trial is con-
sidered a feasible practice in breast cancer survivors.
More specifically, the combination of self-monitoring
(step count) and MI have been shown to be important
strategies for long-term adherence to physical activity
behaviour in people living with cancer. This trial, will
examine the efficacy of these health behaviour change
techniques in self-directed physical activity. This is an
important issue because this is a potentially low cost
intervention which could be applied and implemented
widely if successful. This study is guided by the Self-
Determination Theory [32] and Social Cognitive Theory
[26]. We anticipate that those who adhere to the pro-
gram will be more intrinsically motivated at the end of
the trial in comparison to those who do not. We will
also explore whether the initial motivational orientation
predicts adherence to the physical activity program. In
addition, we would anticipate that successful adherence
to the physical activity program will be associated with
higher levels self-efficacy believes and reduced number
of barriers to be physically active.
The primary outcomes of this study focuses on both
psychological and physiological changes which can trans-
late positively for their breast cancer clinical outcomes.
The study expects the enhancement of their QoL, psycho-
logical health and immune biomarkers in 12 to 24 weeks
self-directed physical activity by pedometor application
combining 12 weeks motivational interviewing.
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